Bicyclic Ion Channel Modulators for Selective Pain Relief
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current sodium channel and calcium channel blockers for pain management have limited efficacy due to side effects such as CNS disturbances, dizziness, nausea, and potentially life-threatening cardiac arrhythmias and cardiac failure, highlighting a need for more potent and side-effect-reduced antagonists.
Innovation Solution
Development of compounds that inhibit voltage-gated sodium and calcium channels, specifically targeting NaV1.1, NaV1.2, NaV1.3, NaV1.4, NaV1.5, NaV1.6, NaV1.7, NaV1.8, NaV1.9, and CaV2.2 channels, with the general formula I, to treat various pain conditions and disorders.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current sodium channel and calcium channel blockers are used for pain management, then pain relief is achieved, but side effects such as CNS disturbances, dizziness, nausea, and cardiac arrhythmias occur
Solution Approach 1:
The patent applies local quality by developing channel blockers with selective affinity for specific sodium channel subtypes (NaV1.3, NaV1.7, NaV1.8) and calcium channel subtypes (CaV2.2) that are particularly involved in pain transmission. This selective targeting allows pain relief while minimizing non-specific side effects associated with broader channel blocking. The compounds are designed to interact preferentially with pain-relevant channel isoforms in sensory neurons, achieving localized therapeutic effect.
Solution Approach 2:
The patent employs parameter changes by systematically modifying the chemical structure of channel blockers to optimize their pharmacological properties. Specific structural parameters such as molecular weight, lipophilicity, and functional group composition are adjusted to enhance binding affinity for pain-related channels while reducing off-target effects. The general formula I compounds represent optimized parameter sets that balance efficacy and safety profiles.
2Adaptability or versatility
If existing channel blockers are used to treat various pain conditions, then therapeutic effect is obtained, but the treatment is limited by side effects and efficacy constraints
Solution Approach 1:
The patent applies universality by developing a series of compounds based on general formula I that can target multiple voltage-gated sodium channel subtypes (NaV1.1-NaV1.9) and calcium channel subtypes (CaV2.2) involved in different pain pathways. This multi-target capability allows a single compound class to address diverse pain conditions including acute, chronic, neuropathic, and inflammatory pain, as well as arrhythmias and neurodegenerative disorders, achieving broad therapeutic coverage without sacrificing efficacy at any specific indication.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
These compounds effectively treat acute, chronic, neuropathic, and inflammatory pain, among other conditions, while minimizing side effects, offering a more potent alternative to existing treatments.
Implementation Method 1
compounds useful as inhibitors of ion channels
Implementation Method 2
inhibitors of voltage-gated sodium and calcium channels
Data Source
AI summary
The present invention relates to bicyclic compounds useful as inhibitors of ion channels. The invention also provides pharmaceutically acceptable compositions comprising the compounds of the invention and methods of using the compositions in the treatment of various disorders.